TGF-β Inhibitor Development

During prostate cancer development, TGF-β acts as both a tumor suppressor and a tumor promoter. A full understanding of the role of TGF-β in prostate cancer development is important for the development of inhibitors targeting TGF-β for the treatment of prostate cancer. At Alfa Cytology, we provide a comprehensive one-stop service for the development of TGF-β inhibitor for prostate cancer.

Introduction to TGF-β Inhibitor

During the development of prostate cancer, TGF-β plays a dual role as both a tumor suppressor and a promoter. In the early stages, TGF-beta exerts its inhibitory effects by reducing cell proliferation in both normal cells and early prostate cancer cells; however, as the disease enters advanced stages, cancer cells gradually become resistant to this growth inhibitory effect of TGF-beta.

Fig. 1 TGF-β regulates proliferation and migration of PCa cells. (Mirzaei, S., et al. 2022)

This change in resistance shifts the role of TGF-β from tumor suppression to promotion of tumor progression, particularly in terms of tumor aggressiveness and metastasis. In advanced prostate cancer, TGF-β not only loses its tumor-suppressive role, but instead may exacerbate the malignant behavior of tumors through mechanisms such as promoting epithelial-mesenchymal transition (EMT) in cancer cells, enhancing immunosuppression in the tumor microenvironment, and promoting tumor angiogenesis.

Importance of TGF-β Inhibitor

A growing body of data from preclinical trials suggests that blocking TGF-β signaling is an effective treatment for tumors. It attenuates Treg-mediated immunosuppression, increases T-cell toxicity, and promotes T-cell penetration into tumor centers, thereby inducing strong anti-tumor immunity and tumor regression.

TGF-β Inhibitor Development for Prostate Cancer

Our Services

Alfa Cytology is committed to providing innovative solutions in the field of prostate cancer treatment, and we have a specialized platform to provide a comprehensive one-stop service for TGF-β inhibitors. Our dedicated team consists of senior scientists and researchers in the field of drug development who have extensive experience in customizing every aspect of drug design to preclinical studies.

Workflow for TGF-β Inhibitor Development

Target Identification and Validation

A comprehensive understanding of the role of TGF-β in disease through literature review and genetic pharmacology approaches, and validation of its efficacy as a drug target using CRISPR/Cas9, siRNA, and other technologies.

Lead Compound Identification

Identify small molecules or biologics capable of inhibiting TGF-β signaling through high-throughput screening, virtual screening, and fragment-based drug design.

Lead Compound Characterization

Utilize biochemical assays and selectivity studies to validate the inhibitory effect of lead compounds on TGF-β activity and assess their selectivity for relevant pathways to minimize off-target effects.

In Vitro Studies

Investigate the effects of lead compounds on TGF-β signaling in cell culture models and analyze their mechanism of action, cytotoxicity and pharmacokinetic properties.

One-stop Solutions for TGF-β Inhibitor Development

Prostate Cancer Models

Prostate cancer modeling services provide researchers with reliable, reproducible and physiologically relevant models.

Preclinical Study

Select optimal animal models for preclinical studies to assess the pharmacokinetics, pharmacodynamics and antitumor efficacy.

Alfa Cytology is a company dedicated to the development of prostate cancer therapies. Our company aims to provide customized one-stop TGF-β inhibitors development services in the field of prostate cancer therapy. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.